April 2024

Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA

BMJ Open 2024;14:e072300 doi: 10.1136/bmjopen-2023-072300

Unadjusted time to all-cause discontinuation was significantly longer with baricitinib treatment versus TNFi (estimated median prescription survival time of 704 days versus 448 days; log-rank P<0.01). This difference increased when only comparing differences for b/tsDMARD-naïve patients treated with baricitinib versus tofacitinib.

Keywords:

August 2023

関節リウマチにおけるJAK阻害薬: バリシチニブの経験

J. Clin. Med. 2023;12(13):4527 doi 10.3390/jcm12134527

This review by Taylor, et al. reviews the long-term safety and efficacy data for baricitinib. Results from several studies showed that baricitinib has greater efficacy and survival compared to TNF inhibitors, and that the rate of CDAI <10 for baricitinib-treated RA patients increased over the course of seven years. Data also showed that remission rates were higher in real-world evidence than in RCTs.

Keywords:

December 2022

合成および生物学的抗リウマチ薬によるRAマネジメントに関する 2022 EULAR リコメンデーション

Ann Rheum Dis. 2022. Epub ahead of print [05/12/2022] doi: 10.1136/ard-2022-223356

Smolen, et al. provide a 2022 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs.

Keywords:

October 2022

JAK阻害薬失敗後: 次のJAK阻害薬か変更か –それが問題だ JAK-pot collaboration レジストリ

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222835

Data from the JAK-pot collaboration of registries show that cycling JAKinibs and switching to a bDMARD appear to have similar effectiveness, after failing the first JAKinib.

Keywords:

July 2022

JAK-pot collaborationにおける19レジストりを基にした 31846名の関節リウマチ患者におけるTNF阻害薬, アバ タセプト, IL-6阻害薬, JAK阻害薬の有効性

Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222586

Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.

Keywords:

June 2022

Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac285

Real-world population-based study shows that a switch to a second JAKinib results in a higher drug retention, as compared to switching to a TNFi, in patients with RA who discontinue original JAKinib therapy.

Keywords:

スイスにおけるRA患者の観察研究で, TNF阻害薬, 機序の 異なる生物学的製剤, tofacitinibの有効性は同等

RMD Open 2020;6:e001174 doi:10.1136/rmdopen-2020-001174

This nested cohort study found that, in Switzerland, there was a generally limited overall drug maintenance for b/tsDMARD options in RA. Using data from SCQM-RA – a prospective longitudinal registry, overall maintenance (drug survival) was calculated for TNFi, bDMARD-OMA or JAKi in patients with RA.After adjusting for potential confounding factors, there was a higher hazard of drug discontinuation with TNFi compared with tofacitinib; no significant difference was observed between non-TNF bDMARDs...

Keywords: